Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61653 |
VPC-13789
|
||
VPC-13789 is a highly potent, selective, and orally bioavailable antiandrogen compound that shows promise for studying and developing therapeutics for castration-resistant prostate cancer (CRPC). In LNCaP cells, VPC-13789 effectively inhibits the transcriptional activity of the androgen receptor (AR) with an IC50 value of 0.19 μM [1]. |